Innogen Pharmaceutical (02591.HK): Efsubaglutide Alfa Completes First Patient Dosing in Phase Ib Teen Obesity Trial

NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (stock code: 2591) announced that, as disclosed in the company's announcement dated 22 June 2026, the group expected to commence the Phase Ib clinical trial of efsubaglutide alfa for the treatment of adolescent obesity in July 2026. The board is pleased to announce that on 28 July 2026, the company successfully completed the first patient enrollment and dosing for this Phase Ib clinical trial, with no safety issues or adverse reactions observed during the observation period.

The announcement noted that the company will continue to provide shareholders and potential investors with latest material developments in accordance with applicable regulatory requirements. A cautionary statement was included that the company cannot guarantee it will ultimately succeed in developing and/or commercializing efsubaglutide alfa for adolescent obesity.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.